GLP1R and diabetes mellitus: Furthermore, we have explored the therapeutic potential of miR-10a/b mimics delivered via a subcutaneous injection in mice, which aligns with the translational approach to diabetes treatment, as current diabetic medications, such as GLP1 receptor agonists (liraglutide and semaglutide), also use subcutaneous injections [46,47].